BioSight
Companies
Esperion Therapeutics, Inc. logo

ESPR

NASDAQANN ARBOR, MI
Esperion Therapeutics, Inc.

Esperion Therapeutics is a commercial-stage biotech company that develops and markets drugs to treat lipid disorders. The company's two main products are bempedoic acid (NEXLETOL) and a combination tablet of bempedoic acid with ezetimibe (NEXLIZET), which are already approved and being sold in the U.S., with international partners handling distribution in other regions. Esperion has limited commercial experience and is heavily dependent on the success of these two products to generate revenue and support its operations.

Price history not yet available for ESPR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar